EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials

Georges Gebrael iD, Neeraj Agarwal, Alicia K Morgans, Randy Vince iD, Umang Swami, Angela Y Jia, Nicholas Zaorsky, Chadi Hage Chehade, Zeynep Irem Ozay, Shawn Malone iD, Scott C Morgan iD, Christopher J D Wallis iD und 12 weitere

Cancer · 2026

DOI: 10.1002/cncr.70236 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer, 2026. Verfasst von Georges Gebrael und 23 weiteren Autor:innen. Beteiligte Einrichtung: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Androgen Receptor Antagonists, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Thiohydantoins. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical studies have shown that outcomes of patients with prostate cancer could vary depending on race. In this study, the authors sought to determine if the treatment effect of apalutamide, an androgen receptor pathway inhibitor (ARPI), on overall survival (OS) varies depending on the race of the patient.

Methods

This pooled analysis includes individual patient data from two phase 3 trials, TITAN and SPARTAN, which randomized patients to androgen deprivation therapy (ADT) ± apalutamide in metastatic hormone‐sensitive and nonmetastatic castration‐resistant prostate cancer, respectively. Race was self‐identified and categorized as Asian, Black, White, and Others categories. The authors applied a stratified (stratification for the trial) multivariable Cox proportional hazards regression model to determine heterogeneity of treatment effect on OS after adjustment for age, performance status, body mass index, T‐ and N‐stage, Gleason score, comorbidities, and exposure to statins and metformin.

Results

Overall, 2190 patients were included: 16.9% patients were Asian, 3.7% were Black, 67.4% were White, and 12.0% were from the Others category. The authors did not find any significant heterogeneity of treatment effect from apalutamide on OS across racial groups (interaction‐ p = .46). Among ADT plus apalutamide‐treated patients, there was no association of race with OS (hazard ratio for Asian, 0.77 [95% CI, 0.56–1.06]; Black, 0.82 [95% CI, 0.49–1.37]; and Others, 1.00 [95% CI, 0.75–1.34], all compared to White).

Conclusions

In this study, the authors did not find any evidence of difference in the treatment effect of apalutamide on OS across patients of different races, although interpretation remains limited by poor representation of racial minorities. Among apalutamide‐treated patients, there was no association of race with OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen Receptor AntagonistsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantThiohydantoinsAgedAged, 80 and overHumansMaleMiddle AgedClinical Trials, Phase III as TopicTreatment OutcomeRacial Groups

Stichwörter der Autor:innen

advanced prostate cancerapalutamidedisparitieshealth care accessmHSPCnmCRPCoverall survivalrace

Substanzen

Androgen Receptor AntagonistsapalutamideThiohydantoins

Autor:innen und Institutionen

  • Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada.
  • Mount Sinai Hospital, University Hospitals Network, University of Toronto, Toronto, Ontario, Canada.
  • University of California Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Georges Gebrael, Randy Vince, Shawn Malone, Scott C Morgan, Christopher J D Wallis, Jason R Brown, Daniel E Spratt, Soumyajit Roy

Zitieren

APA

Gebrael, G., Agarwal, N., Morgans, A. K., Vince, R., Swami, U., Jia, A. Y., Zaorsky, N., Chehade, C. H., Ozay, Z. I., Malone, S., Morgan, S. C., Wallis, C. J. D., Kishan, A. U., Barata, P. C., Chowdhury, S., Garcia, J. A., Sheng, I., Brown, J. R., Small, E. J., …, & Roy, S. (2026). Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials. Cancer. https://doi.org/10.1002/cncr.70236

Vancouver

Gebrael G, Agarwal N, Morgans AK, Vince R, Swami U, Jia AY, et al. Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials. Cancer. 2026. doi:10.1002/cncr.70236

BibTeX
@article{Gebrael2026,
  author = {Gebrael, Georges and Agarwal, Neeraj and Morgans, Alicia K and Vince, Randy and Swami, Umang and Jia, Angela Y and Zaorsky, Nicholas and Chehade, Chadi Hage and Ozay, Zeynep Irem and Malone, Shawn and Morgan, Scott C and Wallis, Christopher J D and Kishan, Amar U and Barata, Pedro C and Chowdhury, Simon and Garcia, Jorge A and Sheng, Iris and Brown, Jason R and Small, Eric J and Sun, Yilun and Shore, Neal D and Saad, Fred and Spratt, Daniel E and Roy, Soumyajit},
  title = {Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70236}
}
Kostenlos starten →